Table 1 Baseline demographics and disease characteristics in all treated patients with MSS mCRC (N = 148)
Patients with MSS mCRC (N = 148) | |
|---|---|
Median age, years (range) | 56 (25–82) |
Female, n (%) | 76 (51) |
ECOG performance status at baseline, n (%) | |
0 | 69 (47) |
1 | 79 (53) |
Median prior lines of therapy (range) | 3 (1–10) |
Prior PD-(L)1/CTLA-4, n (%) | 24 (16) |
Prior regorafenib, n (%) | 30 (20) |
Prior trifluridine/tipiracil, n (%) | 24 (16) |
Prior regorafenib as well as trifluridine/tipiracil, n (%) | 43 (29) |
Prior bevacizumab, n (%) | 120 (81) |
Prior bevacizumab/trifluridine/tipiracil, n (%) | 14 (9) |
Prior radiotherapy, n (%) | 64 (43) |
Multiple metastatic sites, n (%) | 100 (68) |
Peritoneal disease, n (%) | 62 (42) |
BOT dose, n (%) | |
1 mg kg−1 Q6W + BAL (PD-1) Q2W | 67 (45) |
2 mg kg−1 Q6W + BAL (PD-1) Q2W | 81 (55) |
Liver involvement, n (%) | |
Active LM | 25 (17) |
NLM | 123 (83) |
Treated LM | 20 (14) |
No history of LM | 103 (70) |
TMB > 10, n/N (%)1 | 1/40 (3) |
RAS mutation, n (%)1 | 26/45 (58) |
BRAF mutation, n/N (%)1 | 2/45 (4) |
